- The June 30 review of SONUS Pharmaceuticals' New Drug Applicationfor EchoGen Emulsion has been delayed, reports the company. This delay is due to a federal court injunction against the US Food and Drug Administration, which prevents the agency from continuing with approval procedures for EchoGen, and three other ultrasound contrast agents, until 10 days after it answers Citizen Petitions filed by Bracco Diagnostics, DuPont Merck and SONUS, which concern the regulation of ultrasound contrast agents as drugs or devices.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze